@d_mathai

๐ŸŒฟ Medical Director, Psychiatry, Sattva Medicine ๐Ÿ”ฌ Psychedelic Therapy Researcher ๐Ÿ“š Baylor College of Medicine You and your experience matter.

 Miami, Florida
davidmathaimd.com
Joined January 2013
  • Tweets1.4K
  • Following525
  • Followers560
34Media
๐Ÿšจ New publication from our group! "Real-world use of classic and non-classic psychedelics in Hispanic/Latino adults with Obsessive-Compulsive Disorder: International findings from the LATINO Study" @BCMEthics
2
1
2
169
Esketamine and Acceptance and Commitment Therapy (ACT) for Treatment-Resistant Depression: An Intervention-Development Framework and Treatment Manual doi.org/10.1016/j.psyche.202โ€ฆ
3
6
391
Integrating evidence, subject-matter expertise, and consensus in Delphi-based clinical guideline development: sciencedirect.com/science/arโ€ฆ
159
ASKP3 publishes first interdisciplinary consensus standards for IV ketamine treatment in the United States prn.to/4v6GqV0

ASKP3 publishes first interdisciplinary consensus standards for IV ketamine treatment in the United...

/PRNewswire-PRWeb/ -- The American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP3) has published the first Delphi-driven,...

prweb.com
1
2
4
396
Interdisciplinary, Delphi-driven consensus guidelines on the use of intravenous ketamine infusions for depressive disorders from the American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP3): sciencedirect.com/science/arโ€ฆ
1
66
Reported Safety Practices of Publicly Advertised Psychedelic Retreats jamanetwork.com/journals/jamโ€ฆ I find this study could be a useful springboard for deep discussions around safety and ethics, but NOT only from a western medical lens.

Reported Safety Practices of Publicly Advertised Psychedelic Retreats

This qualitative study describes safety precautions reported by representatives of publicly advertised psychedelic retreat organizations.

jamanetwork.com
2
4
190
David Mathai, MD retweeted
JAMA Network Open@JAMANetworkOpenJan 7
Across #PsychedelicRetreats, most organizations conducted medical history screening and recommended medication washout, but safety protocols and health professional involvement varied. ja.ma/45tDQh7
1
2
284
๐Ÿšจ New publication led by the OSU psychedelic center! "๐—จ๐—ฆ ๐—ฑ๐—ฟ๐˜‚๐—ด ๐—ฝ๐—ผ๐—น๐—ถ๐—ฐ๐˜† ๐—ฑ๐—ผ๐—ฒ๐˜€ ๐—ป๐—ผ๐˜ ๐—ฎ๐—น๐—ถ๐—ด๐—ป ๐˜„๐—ถ๐˜๐—ต ๐—ฒ๐˜…๐—ฝ๐—ฒ๐—ฟ๐˜๐˜€โ€™ ๐—ฟ๐—ฎ๐—ป๐—ธ๐—ถ๐—ป๐—ด๐˜€ ๐—ผ๐—ณ ๐—ฑ๐—ฟ๐˜‚๐—ด ๐—ต๐—ฎ๐—ฟ๐—บ๐˜€: ๐—” ๐—บ๐˜‚๐—น๐˜๐—ถ-๐—ฐ๐—ฟ๐—ถ๐˜๐—ฒ๐—ฟ๐—ถ๐—ฎ ๐—ฑ๐—ฒ๐—ฐ๐—ถ๐˜€๐—ถ๐—ผ๐—ป ๐—ฎ๐—ป๐—ฎ๐—น๐˜†๐˜€๐—ถ๐˜€" link.springer.com/article/10โ€ฆ

US drug policy does not align with expertsโ€™ rankings of drug harms: a multi-criteria decision...

Harm Reduction Journal - Background United States drug policy is primarily based on the Controlled Substances Act of 1970 and largely contradicts scientific evidence about how to mitigate...

link.springer.com
1
45
DISCLAIMER: This post is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making decisions related to mental health or treatment options.
30
Link to the pre-proof version of the article: pubmed.ncbi.nlm.nih.gov/4102โ€ฆ

Real-world use of classic and non-classic psychedelics in Hispanic/Latino adults with obsessive-c...

Real-world evidence suggests that H/L adults are exploring psychedelics as a treatment for OCD, though further work is needed to establish the conditions for safe and effective use in this populati...

pubmed.ncbi.nlm.nih.gov
10
David Mathai, MD retweeted
BCM Ethics & Policy@BCMEthics31 Mar 2025
๐Ÿšจ New paper alert! ๐Ÿšจ Check out the latest viewpoint by our Dr. McGuire, scholar Dr. Mathai, and collaborators on minimizing risk and harm in the use of psychedelics. Read more: onlinelibrary.wiley.com/doi/โ€ฆ #Psychedelics #HarmReduction

On Minimizing Risk and Harm in the Use of Psychedelics

Objective This article outlines recommendations from 30 psychedelic researchers on how to create a better psychedelic safety net. Methods A survey of 30 psychedelic researchers asked them to identi...

onlinelibrary.wiley.com
1
1
1
111
David Mathai, MD retweeted
Shayla Love@shayla__love5 Mar 2025
Lots of people have been speculating about Elon Muskโ€™s ketamine use, and so I wrote about what we do know about prolonged, heavy ketamine use in samples of recreational users. Many of these risks are well-known already in psychedelic circles. theatlantic.com/health/archiโ€ฆ

What Ketamine Does to the Human Brain

Excessive use of the drug can make anyone feel like they rule the world.

theatlantic.com
8
31
2
75
8,383
David Mathai, MD retweeted
DoubleBlind
@doubleblindmag3 Mar 2025
Today in The Drop In: Beat-era poet and artist Gerd Sternโ€™s final chapter, new research on why guilt during a trip might actually help you heal, and monkeys tapping into plant medicine. Plus, soul retrieval and what to know before working with Datura. newsletter.doubleblindmag.coโ€ฆ

Are There Benefits to Feeling Shame and Guilt While Tripping?

Plus, everything you need to know about 4-AcO-DMT, Datura, and working out & microdosing

newsletter.doubleblindmag.com
1
1
4
515
โ€œBad tripsโ€ and guilt: Why difficult feelings during psychedelic use might actually be a good thing: Study @d_mathai @sdpnayak @n_sepeda @Drug_Researcher @JHPsychedelics @BCMEthics @unlimited_sci psypost.org/bad-trips-and-guโ€ฆ

"Bad trips" and guilt: Why difficult feelings during psychedelic use might actually be a good thing

Feelings of shame and guilt are surprisingly common during psilocybin experiences, affecting most users. However, a new study reveals that constructively working through these emotions, rather than...

psypost.org
1
1
144
New publication in the Journal of Psychoactive Drugs led by Dr. David Mathai (@d_mathai) exploring emotions of shame and guilt that may arise during someone's psilocybin experience, and their relevance to psychological outcomes.ย tandfonline.com/doi/epdf/10.โ€ฆ
2
11
40
3,050
David Mathai, MD retweeted
BCM Ethics & Policy@BCMEthics12 Feb 2025
Excited to share our health policy scholar Dr. Mathai & collabs' new paper๐Ÿ“„โœจ "Shame, Guilt and Psychedelic Experience: Results from a Prospective, Longitudinal Survey of Real-World #Psilocybin Use"๐Ÿง ๐ŸŒฟ #Psychedelics #MentalHealth tandfonline.com/doi/full/10.โ€ฆ

Shame, Guilt and Psychedelic Experience: Results from a Prospective, Longitudinal Survey of...

The classic psychedelic psilocybin has attracted special interest across clinical and non-clinical settings as a potential tool for mental health. Despite increasing attention to challenging psyche...

tandfonline.com
1
1
2
124
A brief but necessary piece! Grateful to have contributed to this viewpoint with @JulesEvans11 and team.
This Post is from an account that no longer exists. Learn more
1
381
NEW ARTICLE OUT: Shame, Guilt and Psychedelic Experience: Results from a Prospective, Longitudinal Survey of Real-World Psilocybin Use tandfonline.com/eprint/UKECNโ€ฆ

Shame, Guilt and Psychedelic Experience: Results from a Prospective, Longitudinal Survey of...

The classic psychedelic psilocybin has attracted special interest across clinical and non-clinical settings as a potential tool for mental health. Despite increasing attention to challenging psyche...

tandfonline.com
5
5
290
ResearchGate link: researchgate.net/publicationโ€ฆ

(PDF) Shame, Guilt and Psychedelic Experience: Results from a Prospective, Longitudinal Survey of...

PDF | The classic psychedelic psilocybin has attracted special interest across clinical and non-clinical settings as a potential tool for mental health.... | Find, read and cite all the research you...

researchgate.net
49
Load more